Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 3:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 653 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Total Cholesterol Clear all

Conditions: Hypercholesterolemia, Hyperlipidemia, Familial Combined
Interventions: colesevelam HCl tablets and fenofibrate tablets, fenofibrate tablets and Welchol placebo tablets; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 10
States / cities: Longwood, Florida • Ocala, Florida • Winterpark, Florida + 7 more

Conditions: Endometriosis
Interventions: Atorvastatin; Drug
Lead sponsor: Penn State University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Influenza
Interventions: cH15/3, cH4/3, cH5/1N1, cH8/1N1, Saline; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypercholesterolemia, Myopathy
Interventions: Not listed
Lead sponsor: Genomas, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 3
States / cities: San Francisco, California • Hartford, Connecticut • New York, New York

Conditions: Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, Diabetes, Chronic Kidney Disease (CKD), Hypertension, Smoking, Myocardial Infarction (MI), Unstable Angina, Angina, Coronary Artery Disease (CAD), Stroke, Transient Ischemic Attack (TIA), Carotid Stenosis, Peripheral Arterial Disease, Atherosclerosis, Claudication
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 7,658 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 14
States / cities: Little Rock, Arkansas • San Pedro, California • Ventura, California + 11 more

Conditions: Head and Neck Cancer
Interventions: gene therapy, interleukin-2 gene, methotrexate; Biological · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Diabetes Mellitus, Type 2
Interventions: Dietary intervention; Behavioral
Lead sponsor: Physicians Committee for Responsible Medicine; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Atherosclerosis, Hypercholesterolemia
Interventions: Statins, HMG CoA; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 50 Years to 99 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Dementia
Interventions: Atorvastatin (generic Lipitor), placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 60 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cholesterol Ester Storage Disease(CESD), Lysosomal Acid Lipase Deficiency, LAL-Deficiency
Interventions: Sebelipase alfa 0.35 mg/kg, Sebelipase alfa 1 mg/kg, Sebelipase alfa 3 mg/kg; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Stanford, California • New York, New York • Pittsburgh, Pennsylvania

Conditions: Hypercholesterolemia, Aches, Cramps, Weakness
Interventions: Creatine; Dietary Supplement
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Wooster, Ohio

Conditions: Coronary Artery Disease, Cardiovascular Diseases, Smoking
Interventions: Educational Letter Post CT Examination; Other
Lead sponsor: American College of Radiology; Other
Eligibility: 50 Years to 80 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Seattle, Washington

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: Inclisiran sodium 300 mg, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 100 Years
Enrollment: 17,004 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 271
States / cities: Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 214 more

Conditions: Cardiovascular Diseases, Lipid Testing, Primary Prevention of Cardiovascular Disease
Interventions: Mailed patient outreach intervention; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 35 Years to 75 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Flagstaff, Arizona • Chicago, Illinois

Conditions: Hyperlipidemia
Interventions: Evacetrapib, Atorvastatin, Ezetimibe, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 61
States / cities: Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 56 more

Conditions: Primary Hypercholesterolemia, Mixed Dyslipidemia
Interventions: Evolocumab Pre-filled Syringe, Evolocumab AI/pen; Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 21
States / cities: Encino, California • Thousand Oaks, California • Ventura, California + 17 more

Conditions: Hypercholesterolemia
Interventions: Evolocumab, Placebo, Atorvastatin, Ezetimibe, Diet Only; Biological · Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 905 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 41
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 33 more

Conditions: Familial Hypercholesterolemia - Heterozygous
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 6
States / cities: Tucson, Arizona • New York, New York • Winston-Salem, North Carolina + 3 more

Conditions: Serum Cholesterol, Gut Microbiome
Interventions: Milk Polar Lipids, Milk Fat; Other
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years to 50 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Hypercholesterolemia, Atherosclerosis
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years to 100 Years
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Homozygous Familial Hypercholesterolemia
Interventions: lerodalcibep, evolocumab; Drug
Lead sponsor: LIB Therapeutics LLC; Industry
Eligibility: 10 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Evanston, Illinois • Cincinnati, Ohio

Conditions: Stroke, Intracranial Atherosclerosis, Intraplaque Hemorrhage
Interventions: Alirocumab, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: High Cholesterol, High Blood Pressure, Colorectal Cancer, Breast Cancer, Prostate Cancer
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 30 Years to 75 Years
Enrollment: 539 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Epstein-Barr Virus Infection, Infectious Mononucleosis, Herpesvirus
Interventions: Matrix-M1 Adjuvant, EBV gp350-Ferritin Vaccine, Placebo Comparator; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 25 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Bethesda, Maryland • Minneapolis, Minnesota

Search by objective public record fields.

Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol

MicroRNA Activation of LOX-1 Mechanisms in Endometriosis

Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates

DNA Diagnostic System for Statin Safety and Efficacy

Patient and Provider Assessment of Lipid Management Registry

Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer

Effect of a Dietary Intervention on Intracellular Lipid Levels, Insulin Sensitivity, and Glycemic Control in Type 2 Diabetes

Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression

Downmodulating Monocyte Activation for HIV-1 Associated Neurocognitive Disorders (HAND)

Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency

Effectiveness of Creatine in Preventing Muscle Aching From Cholesterol-Lowering Statin Drugs

Impact of Patient-Centered Approach for Communicating Coronary Calcium on Cardiovascular Health

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Promoting Cholesterol Screening

A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol

Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen

Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia

Evaluation of Dietary Milk Polar Lipids on Serum Cholesterol and Gut Microbiota in Healthy Adults

Causes and Natural History of Dyslipidemias

Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH

PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis

Online Trial Examining Validity and Reliability of the Shared Decision Making Process Survey

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons